← Back to your selection

Oxford Science Enterprises

oxfordscienceenterprises.com ↗Activity from announced rounds

Activity in this selectionOct 16, 2026 · Jul 19, 2026

Venture building and investment across Oxford’s deep tech, life sciences and health technology ecosystem.

Turning scientific research into companies

Oxford Science Enterprises builds and funds companies from Oxford’s science ecosystem. It works with university researchers, technology hubs and independent scientific startups, combining company formation with investment from pre-seed through growth. Its stated sectors are deep tech, life sciences and health technology.

Activity recorded in RoundOS

Covered financings include Vivid Dx in diagnostics, Mirae in chronic care, ReEmerge in brain-injury rehabilitation, MCatalysis in fuels and events involving Oxford Quantum Circuits and Quantum Motion. These illustrate the range of recorded scientific businesses; OSE’s own directory describes its broader portfolio.

Sources
Rounds participated in
5
Confirmed lead rounds
1
3 roles undisclosed
New companies
5
First participation on record · 0 follow-on
Funding in participating rounds
$92M
5 disclosed · full round size, not this investor’s share

By stage

Seed3
Series A1
Series C+1

By primary sector

Healthtech3
Agritech1
Climate tech1

By country

United Kingdom4
United States1

Rounds

5 in this selection
ReEmerge, Inc.

ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development.

$37MSeries A
Participant
MCatalysis

MCatalysis develops modular microwave-driven catalytic refining systems that convert distributed hydrocarbon feedstocks, including waste carbon, into drop-in liquid fuels and chemical products for industrial buyers.

$5MSeed
Lead
Vivid Dx

Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions

$15MSeed
Role not disclosed
Mirae

AI-driven continuous care platform for autoimmune disease and other complex chronic conditions

$5.4MSeed
Role not disclosed
Moa Technology

An agricultural biotechnology company focused on discovering novel mode of action herbicides

£22.2MSeries C
Role not disclosed